Table 1.
Part one: performance during phase 2 of the delay radial maze task, third assessment
No cannula | PBS | Scop 6.31 μg | Scop 10.00 μg | Scop 15.85 μg | |
---|---|---|---|---|---|
Arm visits before an error | 3.91 ± 0.29 | 2.05 ± 0.48 | 1.45 ± 0.39 | 1.40 ± 0.35 | 1.25 ± 0.38 |
Mean total number of errors | 2.04 ± 0.29 | 4.50 ± 0.87 | 4.70 ± 0.64 | 6.10 ± 0.93 | 5.20 ± 0.77 |
Errors to first six phase 1 arms (during phase 2) | 1.48 ± 0.22 | 3.70 ± 0.67 | 3.50 ± 0.50 | 4.35 ± 0.60 | 3.75 ± 0.53 |
Errors to remaining six baited phase 2 arms (during phase 2) | 0.56 ± 0.14 | 0.80 ± 0.30 | 1.20 ± 0.27 | 1.75 ± 0.39 | 1.45 ± 0.29 |
Arm visits before an error, mean total number of errors, errors made to the first six arms (phase 1), and errors made to the remaining six baited arms (phase 2) ± SEM after no cannula– infusion-free (No cannula), PBS only (PBS), and three doses of scopolamine (Scop 6.31 μg, Scop 10.00 μg, and Scop 15.85 μg). Infusion volume was 0.15 μl/side.